Parabilis Medicines, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PBLS | IDYA | GENB | O15.F | 1873.HK | 3378.HK | |
|---|---|---|---|---|---|---|
| Market cap | 3.75B | 3.12B | 1.82B | 2.54B | 2.80B | 3.73B |
| P/E (TTM) | — | — | — | — | 16.9 | — |
| Forward P/E | -13.9 | -7.9 | -6.2 | — | 6.2 | — |
| Price/book | 3.6 | 2.9 | 4.0 | 5.2 | 0.6 | 5.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −3.92% | +8.41% | +9.49% | −22.42% | −43.17% | +54.07% |
| Today | +3.79% | +3.29% | +2.24% | 0.00% | +5.04% | +5.13% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PBLS news ›Parabilis Medicines: Bullish On Zolucatetide's Broad Oncology Potential
Explore PBLS’s desmoid tumor potential, PEDESTAL Phase 3 progress, Wnt-driven oncology upside, and why this speculative biotech Buy may matter now. - Zolucatetide gives PBLS potential in desmoid tumors, but it also has other Wnt-driven…
Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript
Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path October 24, 2026 12:00 PM EDTCompany... Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and…
Strategic Desmoid Tumor Education and Access
Discover how medical institutions provide education on desmoid tumors, ensuring patient referrals and expanding access to innovative therapies. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA;…
Managing Desmoid Tumor Challenges
Explore effective approaches in handling fatigue, insomnia, and financial difficulties of patients with desmoid tumors as experts highlight psychosocial support and treatment considerations for quality care. This is a video…
Desmoid Tumors: Advancements and Emerging Therapies | Peer Exchange | AJMC
Experts provide insights on recent ICD-10 code availability for desmoid tumors, its implications on diagnosis, treatment, and coverage decisions, as well as the significance for research, patient care, and health care management…
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Sa
Why Is Parabilis Medicines Stock (PBLS) Up 11% Today?
Parabilis Medicines (PBLS) stock soared higher on Monday after the clinical-stage biopharmaceutical company announced updated study data. This data comes from the company’s clinical trial of zolucatetide as a treatment for patients with…
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoi... Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial…
Parabilis Medicines, Inc. (PBLS) - What Are Analysts Saying About This Stock?
MarketBeat Parabilis Medicines, Inc. (PBLS) - What Are Analysts Saying About This Stock? - Analysts hold a “Moderate Buy” consensus on Parabilis Medicines, with four buy ratings, one strong buy, one hold, and one sell. The
Parabilis Medicines (NASDAQ:PBLS) Stock Price Down 7.6% – What’s Next?
Posted by Michael Walen on Oct 8th, 2026 Parabilis Medicines, Inc. (NASDAQ:PBLS – Get Free Report)’s share price traded down 7.6% during mid-day trading on Thursday. The company traded as low as $26.40 and last traded at $26.62. 145,388…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com7
- defenseworld.net1
- marketbeat.com1
- seekingalpha.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.